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 Research Article
 
Expression of chemokines on the surface of different human endothelia
 
P H I L I P P A  H I L L Y E R  a n d  D A V I D  M A L E
 
Department of Biological Sciences, The Open University, Milton Keynes, UK
 
Summary
 
Expression of chemokines at the endothelial surface depends on their rate of synthesis, the capacity of
the endothelium to bind chemokines and the rate of clearance from the surface. The aim of this study was to
establish how these factors depend on the chemokine and the tissue of origin of the endothelium. Human lung and
dermal microvascular endothelium, saphenous and umbilical vein endothelium, and a bone marrow endothelial
line were assayed 
 
in vitro
 
. Chemokine expression, localization and transport was measured by immunoassay and
confocal microscopy. All endothelia bound CCL3 (MIP-1
 
α
 
), CCL5 (RANTES) and CXCL10 (IP-10). CCL3 and
CCL5 bound at high levels, and CXCL10 bound less strongly. However, the profile of chemokine expression varied
between endothelia, and different chemokines were shown to bind to the endothelial surface by distinct mechanisms.
The half-life of CCL3 and CCL5 at the cell surface was approximately 30 min and chemokines were cleared
primarily by endocytosis into caveolae. Endothelia from different tissues synthesize distinctive sets of chemokines,
but the profile of surface-expressed chemokines also depends on the distinctive characteristics of each endothelia.
These two mechanisms may contribute to the differential recruitment of leucocyte subsets to different tissues.
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 caveolae, chemokine, endocytosis, glycosaminoglycan, human endothelium.
 
Introduction
 
Leucocyte migration is a key step in inflammation, involving
attachment, activation, arrest and extravasation of the leuco-
cytes.
 
1,2
 
 The cells are initially slowed by binding to endothe-
lial selectins, at which stage they may be triggered to migrate
across the endothelium by chemokines expressed on the
endothelial surface.
 
3
 
 The population of leucocytes that enters
a site of inflammation depends both on the inflammatory
stimulus and on the tissue involved. This process is thought to
be determined by the set of chemokines present on the
endothelial surface and studies 
 
in situ
 
 suggest that endothelia
are selective in their chemokine-binding properties.
 
4
 
 To date,
more than 40 different human chemokines have been discov-
ered, which act on a diverse family of chemokine receptors.
 
5,6
 
We recently reported that human endothelia from different
vascular beds have distinctive patterns of chemokine produc-
tion, both in the resting state and following activation with the
cytokines TNF-
 
α
 
, IFN-
 
γ
 
 and TGF-
 
β
 
.
 
7
 
 However, the ability to
express chemokines also depends on the surface characteris-
tics of the endothelium, and the rate at which chemokines are
cleared from the surface. In this study, we examined how
these factors affect chemokine expression.
Many chemokines have a heparin-binding site, by which
they bind to proteoglycans.
 
8–12
 
 Endothelial proteoglycans
consist of a core protein that has been modified post-
translationally by the addition of unbranched glycosamino-
glycan (GAG) side chains.
 
13
 
 There are more than 20 different
core proteins, including the syndecans, the glypicans and
CD44. The GAG that are commonly encountered in human
tissues include chondroitin sulphate, dermatan sulphate, heparan
sulphate and keratan sulphate, of which the most abundant is
the polyanionic species heparan sulphate. Chemokines with a
heparin binding site have been shown to bind with high
affinity to heparan sulphate 
 
in vitro
 
. Binding of chemokines
to heparan sulphate proteoglycans (HSPG) assists in orienta-
tion of the chemokine, which is thought to enhance leucocyte
responses to chemokines.
 
10,12,14
 
 Binding to GAG also allows
high concentrations of chemokines to accumulate in the
correct location as well as aiding presentation to specific
chemokine receptors on leucocytes and providing some pro-
tection from damage by enzymes. It is notable that specific
chemokines bind different types of GAG with different
affinities.
 
11,15
 
 Moreover, endothelia express different GAG
depending on their tissue of origin.
 
16,17
 
 One can therefore
reasonably hypothesize that each endothelium will have a
different chemokine-binding capacity. Varied chemokine
expression could thus act as a method of recruiting particular
leucocyte subsets to specific tissues.
Variations in chemokine synthesis and GAG expression
are just two facets of the functional heterogeneity of endothelia
from different anatomical sites, which also affects chemokine
receptor expression and adhesion molecule expression.
 
7,18,19
 
The functional significance of the numerous endothelial
chemokine receptors is still under investigation, and one possi-
bility is that they are involved in the clearance of chemokines
from the cell surface. Although chemokine clearance is very
important for the control of inflammation and for ensuring
that leucocytes do not become desensitized, the mechanisms
for clearing chemokines have received less attention than
analysis of their secretion and expression.
The aim of this study was to investigate whether chemo-
kine expression depends on the origin of the endothelium and
to examine factors controlling the presentation of inflamma-
tory chemokines.
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Materials and methods
 
Endothelial cells
 
Endothelial cells were isolated from human umbilical veins
(HUVEC) and human adult saphenous veins (SVEC) as described
previously.
 
20,21
 
 Dermal and lung microvascular endothelium
(DMVEC and LMVEC) were purchased from Clonetics/Biowhittaker
(Wokingham, Berkshire, UK). The human bone marrow endothelial
cell line (BMEC) was kindly donated by Babette Weksler of Cornell
University.
 
22
 
 For the distinctive culture conditions of these cells, the
details of their chemokine production profiles, and their expression of
chemokine receptors and adhesion molecules, see Hillyer 
 
et al.
 
7
 
 All
experiments were performed on subcultures of confluent cells
between the second and seventh 
 
in vitro
 
 passage. At this stage the
cells all retained their distinctive morphology, expressed von-
Willebrand factor and had distinctive patterns of GAG expression as
determined using a panel of 21 different lectins. All cells were
cultured in M199 medium, containing 10% foetal bovine serum,
2 mmol/L glutamine, 100 U/mL penicillin and 100 
 
µ
 
g/mL strepto-
mycin for 24 h beforehand and throughout the assays; culture
conditions in the assays, including the substratum, were identical for
each cell type.
 
Chemokine binding assay
 
Confluent monolayers of cells on 96-well microplates were washed
four times in HBSS. Sixty-five microlitres of recombinant human
chemokine CXCL8, CXCL10, CCL2, CCL3, or CCL5 (R & D
Systems, Abingdon, UK) was added in triplicates at 0, 250 and
500 ng/mL in maintenance medium and incubated at 37
 
°
 
C for 1 h.
(Preliminary studies had determined that saturation binding was
achieved after 30 min.) At the end of the period, chemokines were
removed, the cells were washed three times in HBSS at 37
 
°
 
C, and
surface-bound chemokines were then detected by 
 
in situ
 
 ELISA.
 
23
 
The expression of MHC class-I molecules was used as an internal
standard. MHC class-I was detected using 0.5 
 
µ
 
g/mL antibody to the
human MHC class I framework (clone W6/32, Laboratory Vision,
Fremont, CA, USA) in the ELISA. (Previous studies have shown that
MHC class-I surface density varies between the different endothelial
types by less than 20% when assayed in parallel.
 
7
 
) To measure the
rate of decay of chemokines from the cell surface, binding assays
were set up as above, but following removal of the chemokines, cells
were cultured in maintenance medium for up to 150 min before
washing and fixation. All assays were carried out in triplicate and
each experiment was repeated independently two or three times to
show consistent patterns of binding.
 
Digestion of GAG
 
Confluent monolayers were washed three times in HBSS. Then
enzymes were added prior to commencing the chemokine binding
assay. Sixty-five microlitres of 10 U/mL heparinase III, 1 U/mL
chondroitinase ABC or 1 U/mL neuraminidase (diluted in HBSS, all
from Sigma, Poole, UK) was added to triplicate wells for 1 h at 37
 
°
 
C
before being washed off. We have previously used this methodology
and the conditions stated to remove individual GAG from brain
endothelium,
 
24
 
 an endothelial cell type that expresses high levels
of GAG.
 
Immunofluorescence
 
Localization of chemokines within the cells was done using double
immunofluorescence labelling with antichemokine and anticaveolin
antibodies. Cells were grown as confluent monolayers on spots of
NH
 
3
 
-vapour-fixed type-I collagen on glass cover slips. The cells were
then treated with chemokines, according to the protocols given above.
They were washed three times in HBSS (37
 
°
 
C), fixed with 0.25%
glutaraldehyde in PBS for 10 min, blocked with 0.05 mol/L Tris/HCl
(pH 7.5) for 20 min and permeabilized with 0.1% Triton X100 in
PBS for 10 min. The cells were stained with a primary combination
of 1:25 rabbit anticaveolin and 1:50 biotinylated mouse antichemo-
kine for 1 h, and a secondary combination of 1:50 fluorescein-
antirabbit-Ig and 1:100 Texas red–streptavidin for 1 h. All antibodies
were diluted in PBS containing 5 mg/mL bovine serum albumin, and
all wash stages were carried out using three washes in PBS.
 
Results
 
Chemokine binding to endothelial monolayers
 
The levels of chemokine binding to five different endothelial
types, SVEC, BMEC, DMVEC, LMVEC and HUVEC were
determined by 
 
in situ
 
 ELISA. Figure 1 shows the binding of
four different inflammatory chemokines (CCL2, CCL3,
CCL5 and CXCL10) to these endothelial cells. (We also
tested CXCL8 binding, but found that at this level, the
chemokine activated and severely disrupted the endothelial
monolayers.) CCL3 and CCL5 both bound at significant but
differing levels to all five endothelial types, while the two
microvascular endothelia also bound CXCL10. CCL2 did not
bind significantly to any of the endothelia tested.
The pattern of chemokine binding depended on the source
of the endothelium. For example, the BMEC bound similar
amounts of CCL5 and CCL3, whereas using the same con-
ditions, CCL5 bound more strongly to SVEC than did CCL3,
but the converse was true for DMVEC, LMVEC and
HUVEC.
Figure 1 also indicates that CCL3 and CCL5 bind to the
endothelia by different mechanisms. On each endothelium,
doubling of the applied CCL3 concentration from 250 ng/mL
to 500 ng/mL caused a much greater proportionate increase in
CCL3 binding. Typically, the binding at 500 ng/mL was 5–20
times that at 250 ng/mL suggesting that CCL3 uses a co-
operative binding mechanism, whereas CCL5 does not.
To investigate the mechanism of binding of CCL3 and
CCL5, BMEC were predigested with glycosidases before
chemokine binding. The enzymes used were heparinase III,
which cleaves HSPG, chondroitinase ABC lyase, which
cleaves chondroitin sulphate/dermatan sulphate proteoglycans,
and neuraminidase, which cleaves sialic acid from other
glycoproteins. Digestion of HSPG by heparinase III signifi-
cantly reduced the binding of CCL5, but not the binding of
CCL3 (Fig. 2). Chondroitinase and neuraminidase had no
effect on the binding of either chemokine. The results confirm
that CCL5 and CCL3 differ in their binding mechanisms and
show that CCL5-binding is dependent on heparan-sulphate.
To determine whether the chemokines were binding to the
same sites on the endothelial cell surface, we used a competi-
tion assay, attempting to block the binding of 500 ng/mL CCL5
with 0–1000 ng/mL CCL3 or vice versa (i.e. a maximum
twofold molar excess). We found that CCL3 was unable to
block CCL5 binding, but CCL5 caused a small (approxi-
mately 10%) but significant (
 
P
 
 < 0.05) inhibition of CCL3
binding at doses of 250–1000 ng/mL. This suggests that the
two chemokines bind at essentially separate sites on the
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endothelium. In accordance with these findings we found that
CCL5 but not CCL3 (or CCL2) bound to immobilized puri-
fied HSPG. Hence we conclude that CCL5 binds to the
endothelia via HSPG, whereas CCL3 binds to a separate site
using a cooperative binding mechanism. The apparent low
level of surface-expressed CXCL10 was unexpected, particu-
larly since CXCL10 also binds to purified HSPG (data not
shown); later experiments suggested that CXCL10 was being
rapidly cleared from the cell surface.
 
Loss of chemokines from the endothelial surface
 
In order to determine how long chemokines persist on the
endothelial surface, we loaded BMEC with 500 ng/mL CCL3,
CCL5 or CXCL10 for 90 min in culture, and then removed
the chemokines, washed the cells and incubated the cultures
for 0–150 min to allow bound chemokines to detach or be
internalized. At the end of the incubation, cultures were
washed, fixed and the surface-bound chemokines were detected
by ELISA. Figure 3 shows examples of decay curves. From
three independent experiments, we calculated the median
half-life of chemokines on BMEC as 26 min for CCL3 and
27 min for CCL5. Identical experiments using DMVEC gave
very similar surface half-lives for CCL3 and CCL5. Because
of its apparent low level of surface expression, it was not
possible to obtain accurate clearance curves for CXCL10.
The loss of chemokines from the endothelial surface could
be due to endocytosis, or dissociation from the cell surface.
Initial experiments showed that reducing the temperature of
the cells to 4 or 25
 
°
 
C during the incubation with chemokines
resulted in a significant increase in surface expression of
CCL3 and CCL5 (
 
P
 
 < 0.05), suggesting that the endothelial
surface was cleared more effectively at 37
 
°
 
C. To investigate
this further, we carried out identical experiments to those above,
but with the inclusion of inhibitors of endocytosis during the
decay phase. The inhibitors used were chlorpromazine
(targeting clathrin-coated endosomes), nystatin (caveolae),
 
Figure 1
 
Binding of chemokines to endothelia from different tissues. The chemokines CCL3, CCL5, CCL2 and CXCL10 were applied at
(
 

 
) 0, (
 

 
) 250 and (
 

 
) 500 ng/mL to five different human endothelia for 1 h at 37
 
°
 
C and binding was assayed by ELISA. The results are
the mean + SD of triplicate determinations, from at least two experiments, expressed as a percentage of MHC class-I expression (= 100%).
(a) Saphenous vein endothelial cells (SVEC); (b) human umbilical vein endothelial cells (HUVEC); (c) dermal microvascular endothelial
cells (DMVEC); (d) lung microvascular endothelial cells (LMVEC); (e) bone marrow endothelial cells (BMEC). *
 
P
 
 < 0.05.
 
Figure 2
 
Chemokine binding after enzyme digestion of prote-
oglycan. Bone marrow endothelial cell monolayers were digested
with (
 

 
) heparinase, (
 

 
) chondroitinase, (
 

 
) neuraminidase or
(
 

 
) no enzyme for 1 h at 37
 
°
 
C, then 500 ng/mL CCL3 or CCL5
was added for 1 h at 37
 
°
 
C and surface-bound chemokines were
detected by ELISA The results are mean + SD of triplicate deter-
minations. Significance was tested by two-way 
 
ANOVA
 
 with a post
hoc 
 
t
 
-test. *
 
P
 
 < 0.05.
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nocodazole (microtubules) and cytochalasin-D (microfila-
ments). In preliminary experiments, we tested a range of
doses for each inhibitor and established that the levels used in
the experiments did not cause disruption of the endothelial
monolayers during a 2 h incubation period. Figure 4 shows
the combined results from three independent experiments,
each with duplicate determinations, using a 40 min time-point
and CCL3. At this point there was 53% loss of detectable
chemokine, which was substantially inhibited by 25 
 
µ
 
g/mL
nystatin. The data were analysed by 
 
ANOVA
 
 (
 
P
 
 < 0.0005),
followed by Dunnett’s multiple comparison test. Only the
higher dose of nystatin was significantly different from the
untreated control (
 
P
 
 < 0.001). Similar results were observed
in two experiments using CCL5. In parallel we assayed the
supernatants at the end of the incubation for the presence of
dissociated chemokines, and detected only low levels
(2–10 ng/mL) in each case.
Because nystatin substantially inhibits loss of surface
chemokine and since little chemokine can be detected in the
supernatants, this implies that the major proportion of surface
chemokine is removed by endocytosis into caveolae. To
confirm this observation, we carried out double label immuno-
fluorescence with confocal microscopy, to establish whether
applied chemokines and caveolin colocalize within the cells.
Figure 5a,b shows the distribution of CCL5 and CXCL10 in
the cytoplasm of monolayers of BMEC 45 min after removal
of applied chemokine. Most cells have internalized the chemo-
kine and show streams of vesicles converging on the centre of
the cell; this phenomenon is most easily seen on large cells
with extensive cytoplasm. There is also strong staining in the
perinuclear region. This perinuclear staining corresponds to
the expected size and location of the caveosome, an endo-
somal compartment that has been described as a trafficking
point for caveolae in other cell types. At higher magnification
and using dual staining (Fig. 5c,d), the vesicles containing
chemokines were seen to costain with anticaveolin, confirm-
ing that the chemokines were taken up by caveolae, which
appeared at this stage to be attached to the microtubule
 
Figure 3
 
Decay of chemokines from endothelial surface. Bone
marrow endothelial cells were loaded with 500 ng/mL (a) CCL3
or (b) CCL5 for 90 min. The cells were cultured for a further
0–150 min at 37
 
°
 
C before assay of surface-bound chemokines by
ELISA. Each data point shows the mean 
 
±
 
 SD of triplicate deter-
minations. Each curve is representative of three experiments with
similar results.
 
Figure 4
 
Inhibition of chemokine endocytosis. Bone marrow
endothelial cells were loaded with 500 ng/mL CCL3 for 90 min
before removal (
 
t
 
 = 0). Cells were cultured for a further 40 min in
the presence of the stated concentrations of antibiotics (
 
µ
 
g/mL) at
37
 
°
 
C before assay of bound chemokines by ELISA. Pos., positive
control; Nyst., nystatin; Noc., nocodazole; Cyt., cytochalasin-D;
Chl., chlorpromazine; Neg., no antibiotic. Results are mean + SD
from three independent experiments, expressed as the percentage
detectable at 
 
t
 
 = 0. The numbers beneath the bars are the concen-
trations of applied antibiotic (
 
µ
 
g/mL). ***Significant difference
compared with the untreated control at 
 
P
 
 < 0.001.
 
Figure 5
 
Localization of endocytosed chemokines. Micrographs of endocytosed (a) CCL5 and (b) CXCL10 in a monolayer of bone
marrow endothelial cells. The 
 
z
 
-plane is a 1 
 
µ
 
m thick composite section derived by merging two 0.5 
 
µ
 
m confocal sections, running through
the cytoplasm of the cells (cells are typically 2–3 
 
µ
 
m in thickness). Dual label micrographs show caveolin staining of (c) a single cell and
(d) CXCL10 localization. Dual label photomicrogaphs of lung endothelium show caveolin staining of (e) a single cell and (f) CCL5
localization. The vertical arrow in (c) indicates a caveolar vesicle stained for caveolin, which does not contain chemokine. The horizontal
arrows in parts (c–f) indicate examples of vesicles costained for chemokine and caveolin .
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network. Many caveolae did not contain chemokine, but all
small vesicles containing chemokine also stained for caveolin.
In addition to the 50 nm caveolae, many cells had a number
of larger vesicles that stained for chemokine. Some local
caveolin staining at the plasma membrane and strong peri-
nuclear staining was also seen, although the localization of
caveolin in the perinuclear region, and localization of chemo-
kines is different (compare Fig. 5c,d). The pattern of staining
was similar with CCL3, CCL5 and CXCL10, although the
proportion of chemokine in the larger vesicles appeared greater
with CCL3. DMVEC and LMVEC also showed colocaliza-
tion of chemokines and caveolin, although the network of
caveolar vesicles was generally less extensive in these micro-
vascular endothelia (these cells have less cytoplasm and are
less heterogeneous than BMEC). The data confirm that chemo-
kines are taken up into caveolae and suggest that they may be
routed to an endosomal compartment. Because CXCL10 is
clearly being internalized by the cells, we considered the
possibility that the apparent low level of surface CXCL10
expression is due to rapid clearance by receptor-mediated
endocytosis. Hence, we attempted to block the internalization
of CXCL10 using either 5 
 
µ
 
g/mL blocking antibody to
CXCR3 or 1 
 
µ
 
g/mL CXCL11 (I-TAC), a chemokine that also
binds CXCR3 with similar affinity to CXCL10. The blocking
antibody or chemokine were applied 15 min before loading
the endothelium with 500 ng/mL CXCL10 and were main-
tained in the culture for the remainder of the assay. CXCL11
produced a slight increase (
 
∼
 
15%) in detectable surface
CXCL10, but this was not significant in any one assay (using
 
ANOVA
 
). The blocking antibody had no effect. Removal of
CXCL10 from the cell surface does not therefore appear to be
receptor-mediated in the conditions used here.
 
Discussion
 
In the present study, we investigated the ability of endothelia
from different tissues to present chemokines at the cell
surface. It has previously been shown that a subset of chemo-
kines can bind to endothelium via GAG present in the
proteoglycan layer, and it is also known that endothelial cells
from different tissues and different parts of the vascular tree
vary in their expressed proteoglycans
 
18
 
 and level of sulphation
 
25
 
both 
 
in vivo
 
 and 
 
in vitro
 
. These observations led to the
hypothesis that the ability to present chemokines depends on
the endothelial type. This was confirmed for CCL3, CCL5
and CXCL10. Taken together with our previous data on
chemokine production,
 
7
 
 the present study shows that endothe-
lia from different areas of the vasculature synthesize distinct
subsets of chemokines and present some chemokines more
effectively than others. Numerous studies have highlighted
the importance of specific chemokine expression by the high
endothelial cells of lymphoid tissue, which direct the migra-
tion of lymphocyte populations into those tissues. The present
study shows that selective chemokine expression also occurs
in non-lymphoid tissues, and may underlie the distinct patterns
of leucocyte traffic that are seen in different tissues during
inflammation.
The present study also highlighted a distinction between
the ability of endothelium to synthesize chemokines and the
ability to present them. For example, these endothelia all
synthesize CCL2 when stimulated with inflammatory cytokines,
 
7
 
but do not bind CCL2 at the cell surface, although CCL2 does
attach to the extracellular matrix components laminin, colla-
gen and fibronectin.
The data in Figures 1 and 2 confirm that the mechanism of
presentation depends on the chemokine, with CCL5 being
bound via HSPG. Other researchers, using HUVEC, found
that CCL5 binding was reduced by 10–40% by digestion with
heparinase,
 
15
 
 which suggests that HSPG is a common binding
site for CCL5 on different endothelia. We had expected that
CCL3 would also bind via heparan sulphate proteoglycans
because it too has a heparin-binding site
 
26
 
 and soluble GAG
inhibit endothelial binding.
 
15
 
 The failure of heparinase to
prevent CCL3 binding and the limited capacity of CCL5 to
block CCL3 binding to endothelium suggests that the two
chemokines bind to different sites on the endothelia.
Although it is possible that the chemokines bind to different
subsets of GAG, the data suggest that GAG binding is less
important for CCL3 than its attachment to extracellular
matrix proteins. This would explain how endothelia with high
CCL5 binding levels can have low CCL3 binding levels and
vice versa.
Of the other chemokines tested, CXCL10 also has a
heparin-binding site for endothelium.
 
27
 
 We were therefore
surprised at the comparatively low level of CXCL10 detecta-
ble on the endothelial surface; however, Figure 5b shows that
CXCL10 is efficiently removed by endocytosis, which may
account for its low surface expression.
In these studies it is important to distinguish chemokine
binding to cell surface GAG from binding to chemokine
receptors. GAG are abundant on the cell surface, but the
chemokine binding is of moderate affinity; conversely, indi-
vidual chemokine receptors are present at much lower levels
than the GAG, but chemokines bind with higher affinity to
these receptors. The experiments reported here use a rela-
tively high concentration of chemokine (500 ng/mL), which
detects binding to GAG, whereas studies that use low chemo-
kine concentrations provide information on chemokine-
receptor binding. This explains the apparent discrepancies
between some of the studies in this area. For example, we
were unable to detect CCL3 binding to dermal endothelium,
whereas others have been able to detect binding 
 
in situ
 
 using
1–2 ng/mL radiolabelled CCL3.
 
28
 
 The results can be recon-
ciled by stating that CCL2 does bind to dermal endothelium
via the chemokine receptor (presumably CCR5, which is
present on these cells
 
7
 
), but does not bind significantly via
GAG. In the present study, we also investigated how chemo-
kines are lost from the cell surface. CCL3, CCL5 and
CXCL10 all appear to be removed by caveolar endocytosis,
with the majority cleared within 60 min. The rates of clear-
ance were similar for CCL3 and CCL5, but we were unable to
establish the rate of clearance of CXCL10. Interestingly, the
clearance rate of CCL3 and CCL5 was very similar on the
different endothelia in the culture conditions reported here,
although we had found in preliminary experiments that cul-
tures that had been confluent 
 
in vitro
 
 for several days showed
somewhat slower chemokine clearance. It has been debated
whether chemokine clearance is effected by receptor-
mediated endocytosis, and it has been suggested that non-
signalling chemokine receptors, including the Duffy antigen
receptor for chemokines (DARC), and the receptors D6
and CCX-CKR, could each act as scavengers to remove
 Endothelial presentation of chemokines
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extraneous chemokines from the blood and thus prevent
desensitization of circulating leucocytes. The endothelia in
this study express a wide variety of specific chemokine
receptors, including CCR3, CCR5 and CXCR3,
 
7
 
 which bind
to the chemokines used (CCL3, CCL5, CXCL10). Various
functions have been proposed for specific endothelial chemo-
kine receptors, including promoting cell migration, enhancing
or suppressing angiogenesis or mediating chemokine trans-
cytosis; however, we have not been able to consistently
demonstrate these actions on these endothelia. We considered
the possibility, therefore, that a primary function of endothe-
lial chemokine-receptors is to clear the cell surface of excess
chemokines. Interestingly, in accordance with this theory, the
level of expression of the chemokine receptor CXCR3 on
different endothelia was inversely correlated with the level of
its ligand CXCL10, detectable on the endothelial surface (data
not shown). However, we were unable to block CXCL10
endocytosis using a blocking anti-CXCR3 antibody, and
produced only marginal (non-significant) blocking with
CXCL11. Therefore, at the levels used here, it does not
appear that receptor-mediated endocytosis contributes signifi-
cantly to chemokine clearance, although it might do so when
lower levels of chemokine are present. The results are con-
sistent with direct fluid-phase endocytosis into caveolae
and/or caveolar uptake of chemokines attached to surface
GAG/glycoproteins.
In conclusion, endothelia from different tissues selectively
bind particular chemokines, but only a subset of endothelium-
produced chemokines can be effectively presented on the
endothelial surface. Caveolae-mediated endocytosis is impor-
tant in clearing the cell surface of chemokines. This process is
rapid and seen in all types of endothelia studied. The data
highlight the important role that endothelium plays in deter-
mining selective chemokine-expression in different tissues
and hence its potential for controlling the type of inflamma-
tory response and leucocyte migration that occurs in those
tissues.
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